Allon Therapeutics Releases Q3 Operating Results and Provides Corporate Update

Published November 7, 2012

Allon Therapeutics releases Q3 operating results and provides corporate update

Filed under: drug treatment news 2012

Allon also reported that it is on track to advance toward commercialization of its lead neuroprotective drug candidate davunetide as a potential treatment for progressive supranuclear palsy (PSP), a rapidly progressing and fatal degenerative brain …
Read more on The Herald | HeraldOnline.com

ISIS Pharmaceuticals' CEO Discusses Q3 2012 Results – Earnings Call Transcript

Filed under: drug treatment news 2012

This year, we established a relationship with Biogen Idec, for our drugs to treat patients with spinal muscular atrophy and muscular dystrophy, bringing in $ 41 million in cash. Biogen Idec also provides us expertise in the field of neurodegenerative …
Read more on Seeking Alpha

Biogen Hemophilia A Therapy Helps in Fewer Injections

Filed under: drug treatment news 2012

Biogen Idec Inc. (BIIB) and partner Swedish Orphan Biovitrum AB (SOBI) said their hemophilia A therapy controlled bleeding with fewer injections in a late-stage study. The companies plan to apply for U.S. approval early next year. The therapy, long …
Read more on Businessweek

Glaxo, Roche Drugs Help Treat Breast Cancer in Brain

Filed under: drug treatment news 2012

GlaxoSmithKline (GSK) Plc's breast cancer pill Tykerb, used with Roche Holding AG (ROG)'s drug Xeloda, helped treat the disease's spread to the brain, according to a study. The treatments shrank the size of brain tumors by at least 50 percent in two …
Read more on Businessweek